Tokyo, Dec. 1 -- UMIN Clinical Trials Registry (UMIN-CTR) received information related to the study (UMIN000059681) titled 'TecPioneer - Japan: Panel Interview of ONcology practices with Emergent Experience of Teclistamab in the Real World (Japan)' on Dec. 1.
Study Type:
Observational
Primary Sponsor:
Institute - Janssen Pharmaceutical K.K.
Condition:
Condition - Relapsed or refractory multiple myeloma
Classification by malignancy - Malignancy
Genomic information - NO
Objective:
Narrative objectives1 - 1.To characterize teclistamab treatment strategies and administration models, including patient profiles, teclistamab's place in the treatment armamentarium... among Japanese healthcare providers for their patients with RRMM being treated with teclistamab.
2.To characterize how Japanese healthcare providers treating RRMM patients with teclistamab anticipate, monitor and manage treatment-related AEs such as cytokine release syndrome (CRS), neurotoxicity, and infection.
3.To investigate how Japanese healthcare providers evaluate their current teclistamab administration models and how they envision future care models for teclistamab, including in combinations and in earlier lines of therapy.
Basic objectives2 - Others
Eligibility:
Age-lower limit - 18
years-old
<=
Age-upper limit - Not applicable
Gender - Male and Female
Key inclusion criteria - 1.18+ years of age at the time of the study participation.
2.Board certified in oncology or hematology and currently practicing medicine in Japan.
3.Has prescribed and treated at least one (1) patient with teclistamab for relapsed or refractory multiple myeloma in the real-world setting.
4.Japanese-language proficient.
5.Provides verbal consent to all terms of research participation.
6.Willing and able to participate in a recorded web-based video conferencing interview.
Key exclusion criteria - Any individual who does not meet all inclusion criteria.
Target Size - 15
Recruitment Status:
Recruitment status - Preinitiation
Date of protocol fixation - 2025 Year 10 Month 30 Day
Date of IRB - 2025 Year 10 Month 23 Day
Anticipated trial start date - 2025 Year 12 Month 01 Day
Last follow-up date - 2026 Year 12 Month 26 Day
To know more, visit https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000068185
Disclaimer: Curated by HT Syndication.
